Abstract
Generation of cell lines with stable overexpression of ADAMTS9
The plasmids pCEP4 (+)-ADAMTS9 or pCEP4 (+) were transfected into CaCo2 and HCT116 cells using Lipofectamine 2000 reagent according to the manufacturer's protocols (Invitrogen, USA). Forty-eight hours post-transfection, CaCo2 and HCT116 cells were selected for 2-4 weeks with hygromycin (Sigma) at a cells.
Total RNA was extracted from cells and tissues using Trizol reagent (Invitrogen, USA), according to the manufacturer's instructions. RT-PCR was performed as described previously [22] . PCR components assess the overall cDNA content. The primer sequences for ADAMTS9 are 5'-CATGCAGTT TGTATCCTG-3', and 5'-GCGTTCTTTTGAAGTGGACG-3'. RT-PCR was performed for 32 cycles for ADAMTS9 and 23 cycles for GAPDH using Go-Taq (Promega, Madison, WI, USA). Agarose gel electrophoresis (120 V, 25 min) was performed on a 2% agarose gel. Results were analyzed using a BioRad's Gel Doc XR+ system (Bio-Rad, USA).
St. Leon-Rot, Germany) on an ABI 7500 Real-Time PCR System (Applied Biosystems). The expression levels of ADAMTS9 in normal colorectal tissues were set as baseline levels.
Colony formation assay
CaCo2 and HCT116 cells were collect ed, and then plated in six-well plates in triplicate. Forty-eight hours post-transfection, the transfectants were select ed for 2-3 weeks with hygromycin (Sigma) at colony) were counted.
Cell proliferation assay
each), CaCo2 and HCT116 cells were transferred to 96-well plates (2 × 10 3 cells per well, in triplicate). Proliferation was measured using the Cell Counting Kit-8 (CCK-8, Beyotime, Shanghai, China) after 0 h, 24 h, 48 h, and 72 h [24] .
Cell cycle and apoptosis analysis
For cell cycle analysis, CaCo2 and HCT116 cells were cultured overnight in six-well plates at 70-80% Lipofectamine-2000, according to the manufacturer's instructions. Forty-eight hours after transfection, overnight in 70% ice-cold ethanol. Fixed cells were then treated with 50 µg/ml RNase at 37 °C for 30 min, and stained with 50 µg/ml propidium iodide for 30 min at room temperature, in the dark. Data were analyzed by Apoptosis assays were performed using the FITC Annexin V Apoptosis Detection Kit I (BD Biosciences) control vector, were harvested 48 h after transfection. Apoptosis and cell viability were measured by FITCAnnexin V and propidium iodide (PI) staining. Cell populations were categorized as viable (Annexin V-, PI-), early apoptotic (Annexin V+, PI-), or late apoptotic cells (Annexin V+, PI+). Both late and early apoptotic cells were counted together for relative apoptotic changes. All experiments were performed three times.
Cell migra tion assay
size PET membrane. Cells were trypsinized and resuspended in serum-free RPMI 1640 medium at a density of 10 × 10 
Statistical analysis
Statistical analysis was performed using the SPSS software (SPSS Inc., Chicago, IL). The expression of ADAMTS9 in tumor tissues, and its expression in the corresponding normal adjacent tissues, were compared using Student's t-tests. RT-PCR data were analyzed using the 2 method, using GAPDH as a refer ence gene. Data on colony formation, cell proliferation and cell migration are expressed as mean ± SD from three inde- 
Results
Expression of ADAMTS9 at the protein level was detected by IHC in 23 primary tumors and 20 of the corresponding tumor adjacent normal tissues. IPP 6.0 analysis showed that ADAMTS9 protein level was lower in colon tumor tissues than that in tumor adjacent normal tissues (Fig. 1A , p < 0.05). ADAMTS9 expression location is in agreement with these data from the human proteinatlas (http://www.proteinatlas.org/) (Fig. 1B) .
Relative to normal tissue, the expression of ADAMTS9 mRNA was down-regulated in 65.6% (21/32) of colorectal cancer tissues (p < 0.05, Fig. 1C ). However, lower expression of ADAMTS9 (data not shown). According to RT-PCR analysis, ADAMTS9 expression was absent in 3 of the 6 colorectal cell lines tested, and weakly expressed in HCT15 and HT29 cell lines (Fig. 1D ).
We sought to determine whether promoter methylation is involved in ADAMTS9 downregulation in colorectal cancer. Typical CpG islands were found in the promoter region of ADAMTS9 using CpG island analysis software (http://cpgislands.usc.edu) (data not shown). MSP was used to analyze the ADAMTS9 promoter methylation status in CRC. Methylation of the ADAMTS9 promoter was observed in all CRC cell lines, which was consistent with its low expression or absence (Fig. 1D) .
To determine whether ADAMTS9 silencing was a direct result of promoter methylation, we treated HCT116 and CaCo2 cells with Aza and TSA, and then performed MSP analysis. After the demethylation treatment, we observed decreased methylation of the ADAMTS9 promoter, and restored ADAMTS9 expression (Fig. 1E) . We also investigated the level of ADAMTS9 promoter methylation in colorectal cancer tissues. MSP results showed that ADAMTS9 was methylated in 68.75 % (44/64) of primary colorectal cancer tissues, but no methylation was found in normal colorectal tissues (Fig.  1F) .
The frequent silencing of ADAMTS9 in CRC cells and tissue specimens suggested that this gene might be a tumor suppressor. Colony formation assay and CCK8 assays were used to investigate whether ADAMTS9 can inhibit tumor cell growth. Exogenous expression of ADAMTS9 reduced colony formation in CaCo2 and HCT116 cells, relative to cells transfected with the empty vector (Fig. 2C) . In CaCo2 and HCT116 cells overexpressing ADAMTS9, cell
ADAMTS9 induces G0/G1 cell cycle arrest and apoptosis in colorectal cancer cells
cells. Compared to control cells, cells transfected with ADAMTS9 were arrested in the G0/ G1 phase, accompanied by the decrease of cells in G2/M and S phase (Fig. 3A) . Suppression of cell growth in tumors is usually associated with the activation of cell death pathways. The percentage of early and late apoptotic cells increased in cells transfected with ADAMTS9, relative to control cells (Fig. 3B) . The expression of down-stream target genes of the p53 signaling pathway, such as caspase 3, caspase 9, PARP, p21, p27 increased in CRC cell lines transfected with ADAMTS9 (Fig. 3C, 3D ).
Transwell assay was performed using CaCo2 and HCT116 cells to assess the effect of ADAMTS9 on colon cancer migration.The number of cells adhering to the lower membrane of the transwells was lower in cells overexpressing ADAMTS9 than in control cells (p < 0.001, Fig. 4A, 4B ). qPCR and western blot analysis showed that the expression of the epithelial marker E-cadherin was up-regulated in cells overexpressing ADAMTS9, while vimentin was repressed, providing more evidence that ADAMTS9 represses EMT (Fig. 4C, 4D) . The Akt/VEGFA signaling pathway contributes to proliferation and metastasis in colorectal cancer. To gain insight into the possible mechanism of ADAMTS9 in colorectal cancer, we tested the expression levels of key molecules in the Akt/VEGFA signaling pathway by western blot. Total Akt, p-Akt, and VEGFA were down-regulated in CRC cell lines transfected with ADAMTS9 (Fig. 5) .
Discussion
ADAMTS family plays functions roles in extracellular matrix (ECM) assembly and degradation. By acting on a large panel of extracellular substrates, an increasing body of evidence indicates that several members of ADAMTS family shows anti-tumorigenic properties through regulated cell adhesion, proliferation, and migration [25] . Most of ADAMTS family members (ADAMTS1, ADAMTS8, ADAMTS9, ADAMTS12, ADAMTS15 and ADAMTS18) share a complex structural design characterized by the presence of a metalloproteinase domain linked to a variety of specialized ancillary domains, including a series of thrombospondin type 1 (TSP1) repeats [26] [27] [28] . Previous studies reported that ADAMTS genes (e.g. ADAMTS8, ADAMTS12 and AD-AMTS18) were frequently methylated and down-regulated in various carcinomas [29] [30] [31] . ADAMTS1, ADAMTS15 and ADAMTS20 are down-regulated in CRC progress [32] [33] . It has also been shown that the promoters of ADAMTS1, ADAMTS5, ADAMTS9, ADAMTS12, ASDAMTS15 and ADAMTS18 are methylated in CRC, suggesting a decreased expression of the proteins in this state [29] [30] [31] 34] . In contrast, ADAMTS4, and ADAMTS5 are overexpressed in CRC, which might be an invasive mechanism of cancer cells to degrade proteoglycans of ECM [32] . studies found that ADAMTS15 and ADAMTS18 were frequently mutated in CRC cells, but the functions were not clear. Hence, it is of potential clinical value to investigate the expression and methylation of ADAMTS genes in CRC.
ADAMTS9 is an extracellular matrix metalloprotease with proteolytic activity, localizes to the cell surface and in the ECM [35] . ADAMTS9 is silenced or down-regulated in esophageal squamous cell carcinoma, nasopharyngeal carcinoma, and gastric cancer [14] [15] [16] 36] . The down-regulation of ADAMTS9 in multiple carcinomas is due to hypermethylation of promoter CpG islands [37] [38] . Furthermore, ADAMTS9 reduces downstream targets, including p70 ribosomal S6 kinase, eIF4E-binding protein, and downcolorectal cancer cell lines and repressed in 65.6% of colorectal cancer tissues, indicating that a loss of ADAMTS9 expression could lead to colorectal cancer tumorigenesis. MSP revealed that ADAMTS9 promoter methylation was partially responsible for its down-regulation in CRC. Furthermore, down-regulation of ADAMTS9 correlated with promoter methylation in most cell lines. The methylation of ADAMTS9 in SW480 cells showed a limited effect on mRNA expression. This might be caused by the heterogeneity of tumor cells. Aza inhibited promoter methylation and restored the expression of ADAMTS9, suggesting that promoter methylation is a predominant regulatory mechanism of ADAMTS9 inactivation in colorectal cancer.
ADAMTS9 was silenced or down-regulated in colorectal cancer cell lines and human CRC tissue specimens, suggesting that ADAMTS9 might be a potential TSG, and that its that exogenous ADAMTS9 expression in CaCo2 and HCT116 cells induce apoptosis, suppress ADAMTS9 could also reverse EMT. In addition, the mesenchymal marker vimentin was inhibited and E-cadherin was up-regulated by ADAMTS9.Akt pathway plays an important role in cancer development and progression by regulating cell proliferation and apoptosis [39] [40] . We analyzed the relationship between ADAMTS9 and Akt signaling pathway in colorectal cancer. ADAMTS9 inhibited the expression of p-Akt and VEGFA, but up-regulated the expression of p53 in CRC. Whereas p53, another downstream target gene of Akt, is very important tumor suppressor gene in multiple carcinogenosis, these results imply that ADAMTS9 might act as a tumor suppressor in colorectal cancer.
Conclusion
In summary, our results demonstrated that ADAMTS9 expression is frequently silenced by promoter methylation in colorectal cancer cell lines and primary CRC tissues. Expression of ADAMTS9 was restored by pharmacological demethylation. Down-regulation of ADAMTS9 in colorectal cancer increased cell proliferation. ADAMTS9 functions as a tumor suppressor, acting on the Akt/p53 signaling pathway in colorectal carcinogenesis.
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